Skip to Main Content

2,093

Views

12

CrossRef citations to date

0

Altmetric

Letters to the Editor

Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma

Andreas Viardota Department of Internal Medicine III, University Hospital of Ulm, Ulm, GermanyCorrespondence[email protected]

https://orcid.org/0000-0001-9593-6327 View further author information

,

Georg Hessb Department of Hematology, Oncology and Pneumology, Johannes Gutenberg-University, Mainz, GermanyView further author information

,

Ralf C. Bargouc Department of Internal Medicine II, ECTU, University Hospital Würzburg, Würzburg, GermanyView further author information

,

Nicholas J. Morleyd Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, South Yorkshire, UKView further author information

,

Giuseppe Grittie Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, ItalyView further author information

,

Maria-Elisabeth Goebelerc Department of Internal Medicine II, ECTU, University Hospital Würzburg, Würzburg, GermanyView further author information

,

Karim Iskanderf Amgen Inc., Thousand Oaks, CA, USAView further author information

,

David Cohanf Amgen Inc., Thousand Oaks, CA, USAView further author information

,

Alicia Zhangf Amgen Inc., Thousand Oaks, CA, USAView further author information

,

Janet Franklinf Amgen Inc., Thousand Oaks, CA, USAView further author information

&

Luke Coyleg Royal Northshore Hospital and Pathology North, St. Leonards, AustraliaView further author information